Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin.
Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency.
ORAL Mucolytic: Adult: 60-120 mg daily, in 2-3 divided doses. Child: <2 yr: 7.5 mg bid; 2-5 yr: 7.5 mg bid/tid; 6-12 yr: 15 mg bid/tid.
Ambroxol should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambroxol might not be expectorated.
There are no absolute contraindications but in patients with gastric ulceration relative caution should be observed. It is advisable to avoid use during the first trimester of pregnancy.
Occasional gastrointestinal side effects may occur but these are normally mild.
Ambroxol is not advisable to taken during the first trimester of pregnancy. As ambroxol is excreted in breast milk, it is not recommended to be taken while breastfeeding.
Protect from direct light exposure, Store in a dry place at a temperature not exceeding 30°C, Keep out of the reach of children.
.png&w=384&q=75)